-
Finding a Medication for Negative Symptoms in Schizophrenia: Why So Many Failures? Am J Psychiatry. 2026 Mar 01; 183(3):154-155. Marder SR. PMID: 41764061.
-
Dopamine-Blocking Antipsychotics-Time for a New Conversation With Patients? JAMA Psychiatry. 2026 Feb 01; 83(2):111-112. Marder SR, Ostlund S. PMID: 41296326.
-
Rethinking Antipsychotic Comparisons: The Role of Prior Exposure and Tolerability. Am J Psychiatry. 2026 Feb 01; 183(2):90-92. Marder SR, Essock SM. PMID: 41620810.
-
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as an Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE-2) in Patients With Predominant Negative Symptoms. Schizophr Bull. 2026 Jan 16; 52(1). Bugarski-Kirola D, Liu IY, Arango C, Marder SR. PMID: 40181715; PMCID: PMC12809779.
-
Psychosocial Interventions and Functional Recovery in Schizophrenia-Realizing Opportunities Today. J Clin Psychiatry. 2025 Dec 17; 86(4). Tandon R, Barch DM, Buchanan RW, Green MF, Keshavan MS, Marder SR, Nasrallah HA, Vita A. PMID: 41405550.
-
Efficacy and safety of iclepertin for cognitive impairment associated with schizophrenia (CONNEX programme): results from three phase 3 randomised controlled trials. Lancet Psychiatry. 2025 Dec; 12(12):906-920. Keefe RSE, Harvey PD, Correll CU, Falkai P, Hashimoto N, Klein H, Krystal JH, Marder S, Medalia A, Sumiyoshi T, Wang G, Zhang H, Blahova Z, Bichard-Sall I, English BA, Fu E, Gruenenfelder F, Groeschl M, Kimura K, Tang W, von der Goltz C, Fowler C. PMID: 41233083.
-
In These Times. Schizophr Bull. 2025 May 08; 51(3):571. Gold JM, Rowland L, Bansal S, Harvey P, Smith J, Marder S, Galderisi S. PMID: 40227892; PMCID: PMC12061662.
-
Considerations for Streamlining the Pathway Toward Approval of a Cognition Enhancer for Schizophrenia. Schizophr Bull. 2025 Mar 14; 51(2):283-286. Nuechterlein KH, Green MF, Marder SR. PMID: 39982840; PMCID: PMC11908847.
-
Rationale and Challenges for a New Instrument for Remote Measurement of Negative Symptoms. Schizophr Bull Open. 2024 Jan; 5(1):sgae027. Daniel DG, Cohen AS, Harvey PD, Velligan DI, Potter WZ, Horan WP, Moore RC, Marder SR. PMID: 39502136; PMCID: PMC11535854.
-
Cognitive Impairment Associated With Schizophrenia: New Research Agenda. Schizophr Bull Open. 2024 Jan; 5(1):sgae023. Galderisi S, Marder SR. PMID: 39376222; PMCID: PMC11457370.
-
Efficacy of KarXT on negative symptoms in acute schizophrenia: A post hoc analysis of pooled data from 3 trials. Schizophr Res. 2024 12; 274:57-65. Horan WP, Targum SD, Claxton A, Kaul I, Yohn SE, Marder SR, Miller AC, Brannan SK. PMID: 39260339.
-
Does relapse cause illness progression in first-episode psychosis? A review. Schizophr Res. 2024 09; 271:161-168. Kennedy KP, Zito MF, Marder SR. PMID: 39029146.
-
Effects of PDE10A inhibitor MK-8189 in people with an acute episode of schizophrenia: A randomized proof-of-concept clinical trial. Schizophr Res. 2024 08; 270:37-43. Mukai Y, Lupinacci R, Marder S, Snow-Adami L, Voss T, Smith SM, Egan MF. PMID: 38851166.
-
Sustained Treatment Response and Global Improvements With Long-term Valbenazine in Patients With Tardive Dyskinesia. J Clin Psychopharmacol. 2024 Jul-Aug 01; 44(4):353-361. Correll CU, Citrome L, Singer C, Lindenmayer JP, Zinger C, Liang G, Dunayevich E, Marder SR. PMID: 38767901.
-
Implementation of Cognitive Behavioral Therapy for psychosis via telehealth: An expert consultation and clinical service model. Psychol Serv. 2024 Aug; 21(3):461-472. Gaither ML, Bassett ED, Wilson AL, Marder SR, Bradford DW, Bernard JD, Glynn SM. PMID: 38635219.
-
Relapse in clinically stable adult patients with schizophrenia or schizoaffective disorder: evidence-based criteria derived by equipercentile linking and diagnostic test accuracy meta-analysis. Lancet Psychiatry. 2024 01; 11(1):36-46. Siafis S, Brandt L, McCutcheon RA, Gutwinski S, Schneider-Thoma J, Bighelli I, Kane JM, Arango C, Kahn RS, Fleischhacker WW, McGorry P, Carpenter WT, Falkai P, Hasan A, Marder SR, Schooler N, Engel RR, Honer WG, Buchanan RW, Davidson M, Weiser M, Priller J, Davis JM, Howes OD, Correll CU, Leucht S. PMID: 38043562.
-
Negative symptoms in schizophrenia: Newly emerging measurements, pathways, and treatments. Schizophr Res. 2023 08; 258:71-77. Marder SR, Umbricht D. PMID: 37517366.
-
Psychosis among individuals with methamphetamine use disorder is associated with elevated rates of hospitalizations and emergency department visits across an academic health care system. J Subst Use Addict Treat. 2023 08; 151:209033. Zito MF, Fei Z, Zhu Y, Clingan SE, Marder SR, Mooney LJ. PMID: 37011880.
-
Remote Assessment of Negative Symptoms of Schizophrenia. Schizophr Bull Open. 2023 Jan; 4(1):sgad001. Daniel DG, Cohen AS, Velligan D, Harvey PD, Alphs L, Davidson M, Potter W, Kott A, Schooler N, Brodie CR, Moore RC, Lindenmeyer P, Marder SR. PMID: 39145343; PMCID: PMC11207840.
-
Time to Stop Using the Term Relapse in Schizophrenia Clinical Trials. Schizophr Bull Open. 2022 Jan; 3(1):sgac056. Carpenter WT, Buchanan RW, Marder SR. PMID: 39144755; PMCID: PMC11205881.
-
Natural Language Processing: Its Potential Role in Clinical Care and Clinical Research. Schizophr Bull. 2022 09 01; 48(5):958-959. Marder SR. PMID: 35849122; PMCID: PMC9434436.
-
N-Acetylcysteine effects on glutathione and glutamate in schizophrenia: A preliminary MRS study. Psychiatry Res Neuroimaging. 2022 09; 325:111515. Yang YS, Maddock RJ, Zhang H, Lee J, Hellemann G, Marder SR, Green MF. PMID: 35839558.
-
Comparative risks of all-cause mortality for Veterans with schizophrenia with ongoing receipt of clozapine and other antipsychotic medications. Psychiatry Res. 2022 07; 313:114590. Katz IR, Szymanski BR, Marder SR, Shotwell A, Hein TC, McCarthy JF, Bowersox NW. PMID: 35567853.
-
Rare coding variants in ten genes confer substantial risk for schizophrenia. Nature. 2022 04; 604(7906):509-516. Singh T, Poterba T, Curtis D, Akil H, Al Eissa M, Barchas JD, Bass N, Bigdeli TB, Breen G, Bromet EJ, Buckley PF, Bunney WE, Bybjerg-Grauholm J, Byerley WF, Chapman SB, Chen WJ, Churchhouse C, Craddock N, Cusick CM, DeLisi L, Dodge S, Escamilla MA, Eskelinen S, Fanous AH, Faraone SV, Fiorentino A, Francioli L, Gabriel SB, Gage D, Gagliano Taliun SA, Ganna A, Genovese G, Glahn DC, Grove J, Hall MH, Hämäläinen E, Heyne HO, Holi M, Hougaard DM, Howrigan DP, Huang H, Hwu HG, Kahn RS, Kang HM, Karczewski KJ, Kirov G, Knowles JA, Lee FS, Lehrer DS, Lescai F, Malaspina D, Marder SR, McCarroll SA, McIntosh AM, Medeiros H, Milani L, Morley CP, Morris DW, Mortensen PB, Myers RM, Nordentoft M, O'Brien NL, Olivares AM, Ongur D, Ouwehand WH, Palmer DS, Paunio T, Quested D, Rapaport MH, Rees E, Rollins B, Satterstrom FK, Schatzberg A, Scolnick E, Scott LJ, Sharp SI, Sklar P, Smoller JW, Sobell JL, Solomonson M, Stahl EA, Stevens CR, Suvisaari J, Tiao G, Watson SJ, Watts NA, Blackwood DH, Børglum AD, Cohen BM, Corvin AP, Esko T, Freimer NB, Glatt SJ, Hultman CM, McQuillin A, Palotie A, Pato CN, Pato MT, Pulver AE, St Clair D, Tsuang MT, Vawter MP, Walters JT, Werge TM, Ophoff RA, Sullivan PF, Owen MJ, Boehnke M, O'Donovan MC, Neale BM, Daly MJ. PMID: 35396579; PMCID: PMC9805802.
-
Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature. 2022 04; 604(7906):502-508. Trubetskoy V, Pardiñas AF, Qi T, Panagiotaropoulou G, Awasthi S, Bigdeli TB, Bryois J, Chen CY, Dennison CA, Hall LS, Lam M, Watanabe K, Frei O, Ge T, Harwood JC, Koopmans F, Magnusson S, Richards AL, Sidorenko J, Wu Y, Zeng J, Grove J, Kim M, Li Z, Voloudakis G, Zhang W, Adams M, Agartz I, Atkinson EG, Agerbo E, Al Eissa M, Albus M, Alexander M, Alizadeh BZ, Alptekin K, Als TD, Amin F, Arolt V, Arrojo M, Athanasiu L, Azevedo MH, Bacanu SA, Bass NJ, Begemann M, Belliveau RA, Bene J, Benyamin B, Bergen SE, Blasi G, Bobes J, Bonassi S, Braun A, Bressan RA, Bromet EJ, Bruggeman R, Buckley PF, Buckner RL, Bybjerg-Grauholm J, Cahn W, Cairns MJ, Calkins ME, Carr VJ, Castle D, Catts SV, Chambert KD, Chan RCK, Chaumette B, Cheng W, Cheung EFC, Chong SA, Cohen D, Consoli A, Cordeiro Q, Costas J, Curtis C, Davidson M, Davis KL, de Haan L, Degenhardt F, DeLisi LE, Demontis D, Dickerson F, Dikeos D, Dinan T, Djurovic S, Duan J, Ducci G, Dudbridge F, Eriksson JG, Fañanás L, Faraone SV, Fiorentino A, Forstner A, Frank J, Freimer NB, Fromer M, Frustaci A, Gadelha A, Genovese G, Gershon ES, Giannitelli M, Giegling I, Giusti-Rodríguez P, Godard S, Goldstein JI, González Peñas J, González-Pinto A, Gopal S, Gratten J, Green MF, Greenwood TA, Guillin O, Gülöksüz S, Gur RE, Gur RC, Gutiérrez B, Hahn E, Hakonarson H, Haroutunian V, Hartmann AM, Harvey C, Hayward C, Henskens FA, Herms S, Hoffmann P, Howrigan DP, Ikeda M, Iyegbe C, Joa I, Julià A, Kähler AK, Kam-Thong T, Kamatani Y, Karachanak-Yankova S, Kebir O, Keller MC, Kelly BJ, Khrunin A, Kim SW, Klovins J, Kondratiev N, Konte B, Kraft J, Kubo M, Kucinskas V, Kucinskiene ZA, Kusumawardhani A, Kuzelova-Ptackova H, Landi S, Lazzeroni LC, Lee PH, Legge SE, Lehrer DS, Lencer R, Lerer B, Li M, Lieberman J, Light GA, Limborska S, Liu CM, Lönnqvist J, Loughland CM, Lubinski J, Luykx JJ, Lynham A, Macek M, Mackinnon A, Magnusson PKE, Maher BS, Maier W, Malaspina D, Mallet J, Marder SR, Marsal S, Martin AR, Martorell L, Mattheisen M, McCarley RW, McDonald C, McGrath JJ, Medeiros H, Meier S, Melegh B, Melle I, Mesholam-Gately RI, Metspalu A, Michie PT, Milani L, Milanova V, Mitjans M, Molden E, Molina E, Molto MD, Mondelli V, Moreno C, Morley CP, Muntané G, Murphy KC, Myin-Germeys I, Nenadic I, Nestadt G, Nikitina-Zake L, Noto C, Nuechterlein KH, O'Brien NL, O'Neill FA, Oh SY, Olincy A, Ota VK, Pantelis C, Papadimitriou GN, Parellada M, Paunio T, Pellegrino R, Periyasamy S, Perkins DO, Pfuhlmann B, Pietiläinen O, Pimm J, Porteous D, Powell J, Quattrone D, Quested D, Radant AD, Rampino A, Rapaport MH, Rautanen A, Reichenberg A, Roe C, Roffman JL, Roth J, Rothermundt M, Rutten BPF, Saker-Delye S, Salomaa V, Sanjuan J, Santoro ML, Savitz A, Schall U, Scott RJ, Seidman LJ, Sharp SI, Shi J, Siever LJ, Sigurdsson E, Sim K, Skarabis N, Slominsky P, So HC, Sobell JL, Söderman E, Stain HJ, Steen NE, Steixner-Kumar AA, Stögmann E, Stone WS, Straub RE, Streit F, Strengman E, Stroup TS, Subramaniam M, Sugar CA, Suvisaari J, Svrakic DM, Swerdlow NR, Szatkiewicz JP, Ta TMT, Takahashi A, Terao C, Thibaut F, Toncheva D, Tooney PA, Torretta S, Tosato S, Tura GB, Turetsky BI, Üçok A, Vaaler A, van Amelsvoort T, van Winkel R, Veijola J, Waddington J, Walter H, Waterreus A, Webb BT, Weiser M, Williams NM, Witt SH, Wormley BK, Wu JQ, Xu Z, Yolken R, Zai CC, Zhou W, Zhu F, Zimprich F, Atbasoglu EC, Ayub M, Benner C, Bertolino A, Black DW, Bray NJ, Breen G, Buccola NG, Byerley WF, Chen WJ, Cloninger CR, Crespo-Facorro B, et al. PMID: 35396580; PMCID: PMC9392466.
-
Assessment of Negative Symptoms in Clinical Trials of Acute Schizophrenia: Test of a Novel Enrichment Strategy. Schizophr Bull Open. 2022 Jan; 3(1):sgac027. Hopkins SC, Tomioka S, Ogirala A, Loebel A, Koblan KS, Marder SR. PMID: 39144777; PMCID: PMC11250197.
-
Correction: An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. Pharmacopsychiatry. 2022 Mar; 55(2):e1. de Leon J, Schoretsanitis G, Smith RL, Molden E, Solismaa A, Seppälä N, Kopecek M, Švancer P, Olmos I, Ricciardi C, Iglesias-Garcia C, Iglesias-Alonso A, Spina E, Ruan CJ, Wang CY, Wang G, Tang YL, Lin SK, Lane HY, Kim YS, Kim SH, Rajkumar AP, González-Esquivel DF, Jung-Cook H, Baptista T, Rohde C, Nielsen J, Verdoux H, Quiles C, Sanz EJ, De Las Cuevas C, Cohen D, Schulte PFJ, Ertugrul A, Anil Yagcioglu AE, Chopra N, McCollum B, Shelton C, Cotes RO, Kaithi AR, Kane JM, Farooq S, Ng CH, Bilbily J, Hiemke C, López-Jaramillo C, McGrane I, Lana F, Eap CB, Arrojo-Romero M, Radulescu FS, Seifritz E, Every-Palmer S, Bousman CA, Bebawi E, Bhattacharya R, Kelly DL, Otsuka Y, Lazary J, Torres R, Yecora A, Motuca M, Chan SKW, Zolezzi M, Ouanes S, De Berardis D, Grover S, Procyshyn RM, Adebayo RA, Kirilochev OO, Soloviev A, Fountoulakis KN, Wilkowska A, Cubala WJ, Ayub M, Silva A, Bonelli RM, Villagrán-Moreno JM, Crespo-Facorro B, Temmingh H, Decloedt E, Pedro MR, Takeuchi H, Tsukahara M, Gründer G, Sagud M, Celofiga A, Ignjatovic Ristic D, Ortiz BB, Elkis H, Pacheco Palha AJ, LLerena A, Fernandez-Egea E, Siskind D, Weizman A, Masmoudi R, Mohd Saffian S, Leung JG, Buckley PF, Marder SR, Citrome L, Freudenreich O, Correll CU, Müller DJ. PMID: 35052001.
-
Examining racial differences in community integration between black and white homeless veterans. Psychiatry Res. 2022 02; 308:114385. Novacek DM, Wynn JK, Gabrielian S, Glynn SM, Hellemann G, Horan WP, Kern RS, Lee J, Marder SR, Sugar C, Green MF. PMID: 34999292; PMCID: PMC12584930.
-
An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. Pharmacopsychiatry. 2022 Mar; 55(2):73-86. de Leon J, Schoretsanitis G, Smith RL, Molden E, Solismaa A, Seppälä N, Kopecek M, Švancer P, Olmos I, Ricciardi C, Iglesias-Garcia C, Iglesias-Alonso A, Spina E, Ruan CJ, Wang CY, Wang G, Tang YL, Lin SK, Lane HY, Kim YS, Kim SH, Rajkumar AP, González-Esquivel DF, Jung-Cook H, Baptista T, Rohde C, Nielsen J, Verdoux H, Quiles C, Sanz EJ, De Las Cuevas C, Cohen D, Schulte PFJ, Ertugrul A, Anil Yagcioglu AE, Chopra N, McCollum B, Shelton C, Cotes RO, Kaithi AR, Kane JM, Farooq S, Ng CH, Bilbily J, Hiemke C, López-Jaramillo C, McGrane I, Lana F, Eap CB, Arrojo-Romero M, Radulescu FS, Seifritz E, Every-Palmer S, Bousman CA, Bebawi E, Bhattacharya R, Kelly DL, Otsuka Y, Lazary J, Torres R, Yecora A, Motuca M, Chan SKW, Zolezzi M, Ouanes S, De Berardis D, Grover S, Procyshyn RM, Adebayo RA, Kirilochev OO, Soloviev A, Fountoulakis KN, Wilkowska A, Cubala WJ, Ayub M, Silva A, Bonelli RM, Villagrán-Moreno JM, Crespo-Facorro B, Temmingh H, Decloedt E, Pedro MR, Takeuchi H, Tsukahara M, Gründer G, Sagud M, Celofiga A, Ignjatovic Ristic D, Ortiz BB, Elkis H, Pacheco Palha AJ, LLerena A, Fernandez-Egea E, Siskind D, Weizman A, Masmoudi R, Mohd Saffian S, Leung JG, Buckley PF, Marder SR, Citrome L, Freudenreich O, Correll CU, Müller DJ. PMID: 34911124.
-
PANSS Individual Item and Marder Dimension Analyses From a Pivotal Trial of RBP-7000 (Monthly Extended-Release Risperidone) in Schizophrenia Patients. J Clin Psychiatry. 2021 09 21; 82(5). Le Moigne A, Csernansky J, Leadbetter RA, Andorn AC, Graham JA, Heath AT, Walling DP, Newcomer JW, Marder SR. PMID: 34551218.
-
Changing the Face of Schizophrenia. Am J Psychiatry. 2021 07; 178(7):584-585. Marder SR. PMID: 34270342.
-
Antipsychotic discontinuation and recovery: chicken or egg? Psychol Med. 2023 02; 53(3):1134-1135. Pierre JM, Zito MF, Yang YS, Marder SR. PMID: 37132647.
-
Effects of Brexpiprazole Across Symptom Domains in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies. Schizophr Bull Open. 2021 Jan; 2(1):sgab014. Marder SR, Meehan SR, Weiss C, Chen D, Hobart M, Hefting N. PMID: 34901863; PMCID: PMC8650077.
-
Stigma-Personal Views. Schizophr Bull. 2021 01 23; 47(1):1-2. Saks ER, Marder SR. PMID: 32964221; PMCID: PMC7825016.
-
Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments (SMART-CAT) in first-episode schizophrenia patients: Rationale and trial design. Schizophr Res. 2021 04; 230:87-94. Li X, Guo X, Fan X, Feng T, Wang C, Yao Z, Xu X, Chen Z, Wang H, Xie S, He J, Zhuo K, Xiang Q, Cen H, Wang J, Smith RC, Jin H, Keshavan MS, Marder SR, Davis JM, Jiang K, Xu Y, Liu D. PMID: 33279374.
-
The Neurobiology of Treatment-Resistant Schizophrenia: Paths to Antipsychotic Resistance and A Roadmap for Future Research. Focus (Am Psychiatr Publ). 2020 Oct; 18(4):456-465. Potkin SG, Kane JM, Correll CU, Lindenmayer JP, Agid O, Marder SR, Olfson M, Howes OD. PMID: 33343259; PMCID: PMC7725153.
-
Motivational and cognitive factors linked to community integration in homeless veterans: study 1 - individuals with psychotic disorders. Psychol Med. 2022 01; 52(1):169-177. Green MF, Wynn JK, Gabrielian S, Hellemann G, Horan WP, Kern RS, Lee J, Marder SR, Sugar CA. PMID: 32517838.
-
Motivational and cognitive factors linked to community integration in homeless veterans: Study 2 - clinically diverse sample. Psychol Med. 2021 12; 51(16):2915-2922. Wynn JK, Gabrielian S, Hellemann G, Horan WP, Kern RS, Lee J, Marder SR, Sugar CA, Green MF. PMID: 32466807.
-
Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. J Clin Psychiatry. 2020 05 19; 81(3). Schoretsanitis G, Kane JM, Correll CU, Marder SR, Citrome L, Newcomer JW, Robinson DG, Goff DC, Kelly DL, Freudenreich O, Piacentino D, Paulzen M, Conca A, Zernig G, Haen E, Baumann P, Hiemke C, Gründer G, American Society of Clinical Psychopharmacology, Pharmakopsychiatrie TTDMTFOTAFNU. PMID: 32433836.
-
A long-term, open-label study of valbenazine for tardive dyskinesia. CNS Spectr. 2021 08; 26(4):345-353. Lindenmayer JP, Verghese C, Marder SR, Burke J, Jimenez R, Siegert S, Liang GS, O'Brien CF. PMID: 32419679.
-
Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers. Neuropsychopharmacology. 2020 10; 45(11):1842-1850. Kantrowitz JT, Grinband J, Goff DC, Lahti AC, Marder SR, Kegeles LS, Girgis RR, Sobeih T, Wall MM, Choo TH, Green MF, Yang YS, Lee J, Horga G, Krystal JH, Potter WZ, Javitt DC, Lieberman JA. PMID: 32403118; PMCID: PMC7608251.
-
Post hoc analysis of a randomised, placebo-controlled, active-reference 6-week study of brexpiprazole in acute schizophrenia. Acta Neuropsychiatr. 2020 Jun; 32(3):153-158. Marder SR, Eriksson H, Zhao Y, Hobart M. PMID: 32054559.
-
The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. NPJ Schizophr. 2020 Jan 07; 6(1):1. Potkin SG, Kane JM, Correll CU, Lindenmayer JP, Agid O, Marder SR, Olfson M, Howes OD. PMID: 31911624; PMCID: PMC6946650.
-
Rethinking the risks and benefits of long-term maintenance in schizophrenia. Schizophr Res. 2020 Nov; 225:77-81. Zito MF, Marder SR. PMID: 31806525.
-
A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive Dyskinesia. J Clin Psychopharmacol. 2019 Nov/Dec; 39(6):620-627. Marder SR, Singer C, Lindenmayer JP, Tanner CM, Comella CL, Verghese C, Jimenez R, Liang GS, Burke J, O'Brien CF. PMID: 31688452.
-
Schizophrenia. N Engl J Med. 2019 10 31; 381(18):1753-1761. Marder SR, Cannon TD. PMID: 31665579.
-
The characteristics of cognitive neuroscience tests in a schizophrenia cognition clinical trial: Psychometric properties and correlations with standard measures. Schizophr Res Cogn. 2020 Mar; 19:100161. Kraus MS, Gold JM, Barch DM, Walker TM, Chun CA, Buchanan RW, Csernansky JG, Goff DC, Green MF, Jarskog LF, Javitt DC, Kimhy D, Lieberman JA, McEvoy JP, Mesholam-Gately RI, Seidman LJ, Ball MP, Kern RS, McMahon RP, Robinson J, Marder SR, Keefe RSE. PMID: 31832342; PMCID: PMC6889798.
-
Contributions of common genetic variants to risk of schizophrenia among individuals of African and Latino ancestry. Mol Psychiatry. 2020 10; 25(10):2455-2467. Bigdeli TB, Genovese G, Georgakopoulos P, Meyers JL, Peterson RE, Iyegbe CO, Medeiros H, Valderrama J, Achtyes ED, Kotov R, Stahl EA, Abbott C, Azevedo MH, Belliveau RA, Bevilacqua E, Bromet EJ, Byerley W, Carvalho CB, Chapman SB, DeLisi LE, Dumont AL, O'Dushlaine C, Evgrafov OV, Fochtmann LJ, Gage D, Kennedy JL, Kinkead B, Macedo A, Moran JL, Morley CP, Dewan MJ, Nemesh J, Perkins DO, Purcell SM, Rakofsky JJ, Scolnick EM, Sklar BM, Sklar P, Smoller JW, Sullivan PF, Macciardi F, Marder SR, Gur RC, Gur RE, Braff DL, Consortium on the Genetics of Schizophrenia (COGS) Investigators, Nicolini H, Escamilla MA, Vawter MP, Sobell JL, Malaspina D, Lehrer DS, Buckley PF, Rapaport MH, Knowles JA, Genomic Psychiatry Cohort (GPC) Consortium, Fanous AH, Pato MT, McCarroll SA, Pato CN. PMID: 31591465; PMCID: PMC7515843.
-
Brain glutathione levels and age at onset of illness in chronic schizophrenia. Acta Neuropsychiatr. 2019 Dec; 31(6):343-347. Yang YS, Maddock RJ, Lee J, Zhang H, Hellemann G, Narr KL, Marder SR, Green MF. PMID: 31364526.
-
Evaluating visual neuroplasticity with EEG in schizophrenia outpatients. Schizophr Res. 2019 10; 212:40-46. Wynn JK, Roach BJ, McCleery A, Marder SR, Mathalon DH, Green MF. PMID: 31434625; PMCID: PMC6791734.
-
Motivational and cognitive correlates of community integration in homeless veterans entering a permanent supported housing program. Am J Orthopsychiatry. 2020; 90(2):181-192. Horan WP, Wynn JK, Gabrielian S, Glynn SM, Hellemann GS, Kern RS, Lee J, Marder SR, Sugar CA, Green MF. PMID: 31021133; PMCID: PMC6814490.
-
Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia. J Clin Psychiatry. 2019 03 05; 80(2). Kane JM, Agid O, Baldwin ML, Howes O, Lindenmayer JP, Marder S, Olfson M, Potkin SG, Correll CU. PMID: 30840788.
-
History of Psychopharmacology. Annu Rev Clin Psychol. 2019 05 07; 15:25-50. Braslow JT, Marder SR. PMID: 30786241.
-
N-acetylcysteine improves EEG measures of auditory deviance detection and neural synchronization in schizophrenia: A randomized, controlled pilot study. Schizophr Res. 2019 06; 208:479-480. Yang YS, Davis MC, Wynn JK, Hellemann G, Green MF, Marder SR. PMID: 30712814.
-
Parsing components of auditory predictive coding in schizophrenia using a roving standard mismatch negativity paradigm. Psychol Med. 2019 05; 49(7):1195-1206. McCleery A, Mathalon DH, Wynn JK, Roach BJ, Hellemann GS, Marder SR, Green MF. PMID: 30642411; PMCID: PMC6499668.
-
Contribution of Rare Copy Number Variants to Bipolar Disorder Risk Is Limited to Schizoaffective Cases. Biol Psychiatry. 2019 07 15; 86(2):110-119. Charney AW, Stahl EA, Green EK, Chen CY, Moran JL, Chambert K, Belliveau RA, Forty L, Gordon-Smith K, Lee PH, Bromet EJ, Buckley PF, Escamilla MA, Fanous AH, Fochtmann LJ, Lehrer DS, Malaspina D, Marder SR, Morley CP, Nicolini H, Perkins DO, Rakofsky JJ, Rapaport MH, Medeiros H, Sobell JL, Backlund L, Bergen SE, Juréus A, Schalling M, Lichtenstein P, Knowles JA, Burdick KE, Jones I, Jones LA, Hultman CM, Perlis R, Purcell SM, McCarroll SA, Pato CN, Pato MT, Di Florio A, Craddock N, Landén M, Smoller JW, Ruderfer DM, Sklar P. PMID: 30686506; PMCID: PMC6586545.
-
Herpes simplex virus 1 infection and valacyclovir treatment in schizophrenia: Results from the VISTA study. Schizophr Res. 2019 04; 206:291-299. Breier A, Buchanan RW, D'Souza D, Nuechterlein K, Marder S, Dunn W, Preskorn S, Macaluso M, Wurfel B, Maguire G, Kakar R, Highum D, Hoffmeyer D, Coskinas E, Litman R, Vohs JL, Radnovich A, Francis MM, Metzler E, Visco A, Mehdiyoun N, Yang Z, Zhang Y, Yolken RH, Dickerson FB. PMID: 30478008.
-
Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies. Eur Neuropsychopharmacol. 2019 01; 29(1):127-136. Marder S, Fleischhacker WW, Earley W, Lu K, Zhong Y, Németh G, Laszlovszky I, Szalai E, Durgam S. PMID: 30470662.
-
Bifactor Modeling of the Positive and Negative Syndrome Scale: Generalized Psychosis Spans Schizoaffective, Bipolar, and Schizophrenia Diagnoses. Schizophr Bull. 2018 10 17; 44(6):1204-1216. Anderson AE, Marder S, Reise SP, Savitz A, Salvadore G, Fu DJ, Li Q, Turkoz I, Han C, Bilder RM. PMID: 29420822; PMCID: PMC6192503.
-
Understanding the Association Between Negative Symptoms and Performance on Effort-Based Decision-Making Tasks: The Importance of Defeatist Performance Beliefs. Schizophr Bull. 2018 10 17; 44(6):1217-1226. Reddy LF, Horan WP, Barch DM, Buchanan RW, Gold JM, Marder SR, Wynn JK, Young J, Green MF. PMID: 29140501; PMCID: PMC6192468.
-
A dose-finding study of oxytocin using neurophysiological measures of social processing. Neuropsychopharmacology. 2019 01; 44(2):289-294. Wynn JK, Green MF, Hellemann G, Reavis EA, Marder SR. PMID: 30082892; PMCID: PMC6300532.
-
"Will I need to take these medications for the rest of my life?" World Psychiatry. 2018 Jun; 17(2):165-166. Marder SR, Zito MF. PMID: 29856554; PMCID: PMC5980574.
-
Reliability and validity of the self-report version of the apathy evaluation scale in first-episode Psychosis: Concordance with the clinical version at baseline and 12 months follow-up. Psychiatry Res. 2018 09; 267:140-147. Faerden A, Lyngstad SH, Simonsen C, Ringen PA, Papsuev O, Dieset I, Andreassen OA, Agartz I, Marder SR, Melle I. PMID: 29906681.
-
The Importance of Adequately Powered Clinical Studies: Response to Khan et al. Am J Psychiatry. 2018 02 01; 175(2):188-189. Marder SR, Laughren T, Romano SJ. PMID: 29385831.
-
Disparity between General Symptom Relief and Remission Criteria in the Positive and Negative Syndrome Scale (PANSS): A Post-treatment Bifactor Item Response Theory Model. Innov Clin Neurosci. 2017 Dec 01; 14(11-12):41-53. Anderson AE, Reise SP, Marder SR, Mansolf M, Han C, Bilder RM. PMID: 29410936; PMCID: PMC5788250.
-
The effects of curcumin on brain-derived neurotrophic factor and cognition in schizophrenia: A randomized controlled study. Schizophr Res. 2018 05; 195:572-573. Wynn JK, Green MF, Hellemann G, Karunaratne K, Davis MC, Marder SR. PMID: 28965778.
-
A 10-minute measure of global cognition: Validation of the Brief Cognitive Assessment Tool for Schizophrenia (B-CATS). Schizophr Res. 2018 05; 195:327-333. Hurford IM, Ventura J, Marder SR, Reise SP, Bilder RM. PMID: 28918221.
-
Risperidone versus olanzapine among patients with schizophrenia participating in supported employment: Eighteen-month outcomes. J Psychiatr Res. 2017 12; 95:299-307. Noordsy DL, Glynn SM, Sugar CA, O'Keefe CD, Marder SR. PMID: 28942217; PMCID: PMC5653420.
-
Why Are Innovative Drugs Failing in Phase III? Am J Psychiatry. 2017 Sep 01; 174(9):829-831. Marder SR, Laughren T, Romano SJ. PMID: 28859511.
-
Placebo Response and Practice Effects in Schizophrenia Cognition Trials. JAMA Psychiatry. 2017 08 01; 74(8):807-814. Keefe RSE, Davis VG, Harvey PD, Atkins AS, Haig GM, Hagino O, Marder S, Hilt DC, Umbricht D. PMID: 28636694; PMCID: PMC5710557.
-
Assessment of Suicidal Ideation and Behavior: Report of the International Society for CNS Clinical Trials and Methodology Consensus Meeting. J Clin Psychiatry. 2017 Jun; 78(6):e638-e647. Chappell PB, Stewart M, Alphs L, DiCesare F, DuBrava S, Harkavy-Friedman J, Lim P, Ratcliffe S, Silverman MM, Targum SD, Marder SR. PMID: 28682533.
-
A Cruel Irony for Clinicians Who Treat Depression. Am J Psychiatry. 2017 05 01; 174(5):409-410. Marder SR, Gitlin MJ. PMID: 28457149.
-
KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. Am J Psychiatry. 2017 05 01; 174(5):476-484. Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, Burke J, Liang GS, O'Brien CF. PMID: 28320223.
-
Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017 03 18; 389(10074):1103-1113. Németh G, Laszlovszky I, Czobor P, Szalai E, Szatmári B, Harsányi J, Barabássy Á, Debelle M, Durgam S, Bitter I, Marder S, Fleischhacker WW. PMID: 28185672.
-
The current conceptualization of negative symptoms in schizophrenia. World Psychiatry. 2017 Feb; 16(1):14-24. Marder SR, Galderisi S. PMID: 28127915; PMCID: PMC5269507.
-
Improving measurement of attributional style in schizophrenia; A psychometric evaluation of the Ambiguous Intentions Hostility Questionnaire (AIHQ). J Psychiatr Res. 2017 06; 89:48-54. Buck B, Iwanski C, Healey KM, Green MF, Horan WP, Kern RS, Lee J, Marder SR, Reise SP, Penn DL. PMID: 28160626.
-
Bitopertin in Negative Symptoms of Schizophrenia-Results From the Phase III FlashLyte and DayLyte Studies. Biol Psychiatry. 2017 07 01; 82(1):8-16. Bugarski-Kirola D, Blaettler T, Arango C, Fleischhacker WW, Garibaldi G, Wang A, Dixon M, Bressan RA, Nasrallah H, Lawrie S, Napieralski J, Ochi-Lohmann T, Reid C, Marder SR. PMID: 28117049.
-
Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies. Acta Neuropsychiatr. 2017 Oct; 29(5):278-290. Marder SR, Hakala MJ, Josiassen MK, Zhang P, Ouyang J, Weiller E, Weiss C, Hobart M. PMID: 27846922.
-
How Occupationally High-Achieving Individuals With a Diagnosis of Schizophrenia Manage Their Symptoms. Psychiatr Serv. 2017 Apr 01; 68(4):324-329. Cohen AN, Hamilton AB, Saks ER, Glover DL, Glynn SM, Brekke JS, Marder SR. PMID: 27842472.
-
An RCT Evaluating the Effects of Skills Training and Medication Type on Work Outcomes Among Patients With Schizophrenia. Psychiatr Serv. 2017 03 01; 68(3):271-277. Glynn SM, Marder SR, Noordsy DL, O'Keefe C, Becker DR, Drake RE, Sugar CA. PMID: 27799019.
-
Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia. Schizophr Res. 2017 04; 182:90-97. Dunayevich E, Buchanan RW, Chen CY, Yang J, Nilsen J, Dietrich JM, Sun H, Marder S. PMID: 27789188.
-
Older Brains are Different: Brain-Behavior Studies and Their Clinical Utility. Am J Geriatr Psychiatry. 2017 01; 25(1):11-12. Sultzer DL, Marder SR. PMID: 28231870.
-
Constance E. Lieber, Theodore R. Stanley, and the Enduring Impact of Philanthropy on Psychiatry Research. Biol Psychiatry. 2016 07 15; 80(2):84-86. Krystal JH, Abi-Dargham A, Akbarian S, Arnsten AFT, Barch DM, Bearden CE, Braff DL, Brown ES, Bullmore ET, Carlezon WA, Carter CS, Cook EH, Daskalakis ZJ, DiLeone RJ, Duman RS, Grace AA, Hariri AR, Harrison PJ, Hiroi N, Kenny PJ, Kleinman JE, Krystal AD, Lewis DA, Lipska BK, Marder SR, Mason GF, Mathalon DH, McClung CA, McDougle CJ, McIntosh AM, McMahon FJ, Mirnics K, Monteggia LM, Narendran R, Nestler EJ, Neumeister A, O'Donovan MC, Öngür D, Pariante CM, Paulus MP, Pearlson G, Phillips ML, Pine DS, Pizzagalli DA, Pletnikov MV, Ragland JD, Rapoport JL, Ressler KJ, Russo SJ, Sanacora G, Sawa A, Schatzberg AF, Shaham Y, Shamay-Tsoory SG, Sklar P, State MW, Stein MB, Strakowski SM, Taylor SF, Turecki G, Turetsky BI, Weissman MM, Zachariou V, Zarate CA, Zubieta JK. PMID: 27346079; PMCID: PMC6150945.
-
Task-related fMRI responses to a nicotinic acetylcholine receptor partial agonist in schizophrenia: A randomized trial. Prog Neuropsychopharmacol Biol Psychiatry. 2016 11 03; 71:66-75. Barch DM, Marder SR, Harms MP, Jarskog LF, Buchanan RW, Cronenwett W, Chen LS, Weiss M, Maguire RP, Pezous N, Feuerbach D, Lopez-Lopez C, Johns DR, Behrje RB, Gomez-Mancilla B. PMID: 27371157; PMCID: PMC6432789.
-
Clozapine and risperidone in moderately refractory schizophrenia: a 6-month randomized double-blind comparison. J Clin Psychiatry. 2016 May; 77(5):628-34. Schooler NR, Marder SR, Chengappa KN, Petrides G, Ames D, Wirshing WC, McMeniman M, Baker RW, Parepally H, Umbricht D, Kane JM. PMID: 27035871.
-
Alpha-7 nicotinic agonist improves cognition in schizophrenia. Evid Based Ment Health. 2016 05; 19(2):60. Marder SR. PMID: 26872633; PMCID: PMC10699426.
-
Community Evidence of Clozapine's Effectiveness. Am J Psychiatry. 2016 Feb 01; 173(2):103-4. Marder SR. PMID: 26844790.
-
Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia. Schizophr Bull. 2016 Jan; 42(1):19-33. Keefe RS, Haig GM, Marder SR, Harvey PD, Dunayevich E, Medalia A, Davidson M, Lombardo I, Bowie CR, Buchanan RW, Bugarski-Kirola D, Carpenter WT, Csernansky JT, Dago PL, Durand DM, Frese FJ, Goff DC, Gold JM, Hooker CI, Kopelowicz A, Loebel A, McGurk SR, Opler LA, Pinkham AE, Stern RG. PMID: 26362273; PMCID: PMC4681562.
-
The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerations. Psychiatry Res. 2015 Oct 30; 229(3):760-70. Mohamed S, Johnson GR, Vertrees JE, Guarino PD, Weingart K, Young IT, Yoon J, Gleason TC, Kirkwood KA, Kilbourne AM, Gerrity M, Marder S, Biswas K, Hicks P, Davis LL, Chen P, Kelada A, Huang GD, Lawrence DD, LeGwin M, Zisook S. PMID: 26279130.
-
Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial. JAMA Psychiatry. 2015 Aug; 72(8):822-9. Subotnik KL, Casaus LR, Ventura J, Luo JS, Hellemann GS, Gretchen-Doorly D, Marder S, Nuechterlein KH. PMID: 26107752; PMCID: PMC5065351.
-
Effort-Based Decision-Making Paradigms for Clinical Trials in Schizophrenia: Part 1—Psychometric Characteristics of 5 Paradigms. Schizophr Bull. 2015 Sep; 41(5):1045-54. Reddy LF, Horan WP, Barch DM, Buchanan RW, Dunayevich E, Gold JM, Lyons N, Marder SR, Treadway MT, Wynn JK, Young JW, Green MF. PMID: 26142081; PMCID: PMC4535649.
-
Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia. Schizophr Bull. 2016 Mar; 42(2):335-43. Walling D, Marder SR, Kane J, Fleischhacker WW, Keefe RS, Hosford DA, Dvergsten C, Segreti AC, Beaver JS, Toler SM, Jett JE, Dunbar GC. PMID: 26071208; PMCID: PMC4753586.
-
A Phase II study of a histamine H₃ receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy. Schizophr Res. 2015 May; 164(1-3):136-42. Jarskog LF, Lowy MT, Grove RA, Keefe RS, Horrigan JP, Ball MP, Breier A, Buchanan RW, Carter CS, Csernansky JG, Goff DC, Green MF, Kantrowitz JT, Keshavan MS, Laurelle M, Lieberman JA, Marder SR, Maruff P, McMahon RP, Seidman LJ, Peykamian MA. PMID: 25728831.
-
Ellen Stover. Neuropsychopharmacology. 2014 Dec; 39(13):3132. Nemeroff CB, Marder SR, Lieberman J. PMID: 25381709; PMCID: PMC4229591.
-
Efficacy of lurasidone across five symptom dimensions of schizophrenia: pooled analysis of short-term, placebo-controlled studies. Eur Psychiatry. 2015 Jan; 30(1):26-31. Loebel A, Cucchiaro J, Silva R, Mao Y, Xu J, Pikalov A, Marder SR. PMID: 25280429.
-
Restrictive symptomatic inclusion criteria create barriers to clinical research in schizophrenia negative symptoms: an analysis of the CATIE dataset. Eur Neuropsychopharmacol. 2014 Oct; 24(10):1615-21. Dunayevich E, Chen CY, Marder SR, Rabinowitz J. PMID: 25172269.
-
Learning from people with schizophrenia. Schizophr Bull. 2014 Nov; 40(6):1185-6. Marder SR, Freedman R. PMID: 24973131; PMCID: PMC4193727.
-
Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent negative or disorganized thought symptoms. Psychiatry Res. 2014 Aug 15; 218(1-2):219-24. Edgar CJ, Blaettler T, Bugarski-Kirola D, Le Scouiller S, Garibaldi GM, Marder SR. PMID: 24809242.
-
Perspective: Retreat from the radical. Nature. 2014 Apr 03; 508(7494):S18. Marder SR. PMID: 24695331.
-
Schizophrenia--time to commit to policy change. Schizophr Bull. 2014 Apr; 40 Suppl 3:S165-94. Fleischhacker WW, Arango C, Arteel P, Barnes TR, Carpenter W, Duckworth K, Galderisi S, Halpern L, Knapp M, Marder SR, Moller M, Sartorius N, Woodruff P. PMID: 24778411; PMCID: PMC4002061.
-
Oxytocin-augmented social cognitive skills training in schizophrenia. Neuropsychopharmacology. 2014 Aug; 39(9):2070-7. Davis MC, Green MF, Lee J, Horan WP, Senturk D, Clarke AD, Marder SR. PMID: 24637803; PMCID: PMC4104336.
-
Defining and measuring negative symptoms of schizophrenia in clinical trials. Eur Neuropsychopharmacol. 2014 May; 24(5):737-43. Marder SR, Kirkpatrick B. PMID: 24275698.
-
The reliability and validity of the MATRICS functional assessment battery. Schizophr Bull. 2014 Sep; 40(5):1047-52. Velligan DI, Fredrick M, Mintz J, Li X, Rubin M, Dube S, Deshpande SN, Trivedi JK, Gautam S, Avasthi A, Kern RS, Marder SR. PMID: 24214931; PMCID: PMC4133666.
-
Psychopharmacology of the negative symptoms: current status and prospects for progress. Eur Neuropsychopharmacol. 2014 May; 24(5):788-99. Davis MC, Horan WP, Marder SR. PMID: 24252823.
-
Clinical trials for negative symptoms--emerging directions and unresolved issues. Schizophr Res. 2013 Nov; 150(2-3):327. Marder SR, Rabinowitz J, Kapur S. PMID: 24209763.
-
Monitoring treatment and managing adherence in schizophrenia. J Clin Psychiatry. 2013 Oct; 74(10):e21. Marder SR. PMID: 24229761.
-
Adapting social neuroscience measures for schizophrenia clinical trials, part 3: fathoming external validity. Schizophr Bull. 2013 Nov; 39(6):1211-8. Olbert CM, Penn DL, Kern RS, Lee J, Horan WP, Reise SP, Ochsner KN, Marder SR, Green MF. PMID: 24072806; PMCID: PMC3796091.
-
Adapting social neuroscience measures for schizophrenia clinical trials, Part 2: trolling the depths of psychometric properties. Schizophr Bull. 2013 Nov; 39(6):1201-10. Kern RS, Penn DL, Lee J, Horan WP, Reise SP, Ochsner KN, Marder SR, Green MF. PMID: 24072805; PMCID: PMC3796089.
-
Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. Schizophr Res. 2013 Nov; 150(2-3):328-33. Marder SR, Alphs L, Anghelescu IG, Arango C, Barnes TR, Caers I, Daniel DG, Dunayevich E, Fleischhacker WW, Garibaldi G, Green MF, Harvey PD, Kahn RS, Kane JM, Keefe RS, Kinon B, Leucht S, Lindenmayer JP, Malhotra AK, Stauffer V, Umbricht D, Wesnes K, Kapur S, Rabinowitz J. PMID: 24028744.
-
Pharmacological approaches to treating negative symptoms: a review of clinical trials. Schizophr Res. 2013 Nov; 150(2-3):346-52. Arango C, Garibaldi G, Marder SR. PMID: 23938176.
-
Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: a CATIE analysis. Schizophr Res. 2013 Nov; 150(2-3):339-42. Rabinowitz J, Berardo CG, Bugarski-Kirola D, Marder S. PMID: 23899997.
-
Effects of single dose intranasal oxytocin on social cognition in schizophrenia. Schizophr Res. 2013 Jul; 147(2-3):393-7. Davis MC, Lee J, Horan WP, Clarke AD, McGee MR, Green MF, Marder SR. PMID: 23676253.
-
The genomic psychiatry cohort: partners in discovery. Am J Med Genet B Neuropsychiatr Genet. 2013 Jun; 162B(4):306-12. Pato MT, Sobell JL, Medeiros H, Abbott C, Sklar BM, Buckley PF, Bromet EJ, Escamilla MA, Fanous AH, Lehrer DS, Macciardi F, Malaspina D, McCarroll SA, Marder SR, Moran J, Morley CP, Nicolini H, Perkins DO, Purcell SM, Rapaport MH, Sklar P, Smoller JW, Knowles JA, Genomic Psychiatry Cohort Consortium, Pato CN. PMID: 23650244; PMCID: PMC3729260.
-
Apathy, poor verbal memory and male gender predict lower psychosocial functioning one year after the first treatment of psychosis. Psychiatry Res. 2013 Nov 30; 210(1):55-61. Faerden A, Barrett EA, Nesvåg R, Friis S, Finset A, Marder SR, Ventura J, Andreassen OA, Agartz I, Melle I. PMID: 23489592; PMCID: PMC4066735.
-
Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia. Neuropsychopharmacology. 2013 Jun; 38(7):1245-52. Jarskog LF, Dong Z, Kangarlu A, Colibazzi T, Girgis RR, Kegeles LS, Barch DM, Buchanan RW, Csernansky JG, Goff DC, Harms MP, Javitt DC, Keefe RS, McEvoy JP, McMahon RP, Marder SR, Peterson BS, Lieberman JA. PMID: 23325325; PMCID: PMC3656368.
-
Clinician perceptions, expectations, and management of negative symptoms in schizophrenia. J Clin Psychiatry. 2013 Jan; 74(1):e01. Marder SR. PMID: 23419229.
-
Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building. J Pharmacokinet Pharmacodyn. 2012 Aug; 39(4):393-414. Sherer EA, Sale ME, Pollock BG, Belani CP, Egorin MJ, Ivy PS, Lieberman JA, Manuck SB, Marder SR, Muldoon MF, Scher HI, Solit DB, Bies RR. PMID: 22767341; PMCID: PMC3400037.
-
Clinical instruments to evaluate and guide treatment in schizophrenia. Handb Exp Pharmacol. 2012; (213):1-10. Marder SR. PMID: 23027410.
-
Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr Res. 2012 Apr; 136(1-3):25-31. Javitt DC, Buchanan RW, Keefe RS, Kern R, McMahon RP, Green MF, Lieberman J, Goff DC, Csernansky JG, McEvoy JP, Jarskog F, Seidman LJ, Gold JM, Kimhy D, Nolan KS, Barch DS, Ball MP, Robinson J, Marder SR. PMID: 22169248.
-
Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach. J Clin Psychiatry. 2011 Dec; 72(12):1616-27. Glick ID, Correll CU, Altamura AC, Marder SR, Csernansky JG, Weiden PJ, Leucht S, Davis JM. PMID: 22244023.
-
Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? Schizophr Bull. 2013 Mar; 39(2):417-35. Keefe RS, Buchanan RW, Marder SR, Schooler NR, Dugar A, Zivkov M, Stewart M. PMID: 22114098; PMCID: PMC3576170.
-
Advancing drug discovery for schizophrenia. Ann N Y Acad Sci. 2011 Oct; 1236:30-43. Marder SR, Roth B, Sullivan PF, Scolnick EM, Nestler EJ, Geyer MA, Welnberger DR, Karayiorgou M, Guidotti A, Gingrich J, Akbarian S, Buchanan RW, Lieberman JA, Conn PJ, Haggarty SJ, Law AJ, Campbell B, Krystal JH, Moghaddam B, Sawa A, Saw A, Caron MG, George SR, Allen JA, Solis M. PMID: 22032400; PMCID: PMC3787879.
-
Efficacy and specificity of social cognitive skills training for outpatients with psychotic disorders. J Psychiatr Res. 2011 Aug; 45(8):1113-22. Horan WP, Kern RS, Tripp C, Hellemann G, Wynn JK, Bell M, Marder SR, Green MF. PMID: 21377168; PMCID: PMC4064828.
-
Lessons from MATRICS. Schizophr Bull. 2011 Mar; 37(2):233-4. Marder SR. PMID: 21325472; PMCID: PMC3044624.
-
Evaluation of functionally meaningful measures for clinical trials of cognition enhancement in schizophrenia. Am J Psychiatry. 2011 Apr; 168(4):400-7. Green MF, Schooler NR, Kern RS, Frese FJ, Granberry W, Harvey PD, Karson CN, Peters N, Stewart M, Seidman LJ, Sonnenberg J, Stone WS, Walling D, Stover E, Marder SR. PMID: 21285142.
-
Methodological issues in negative symptom trials. Schizophr Bull. 2011 Mar; 37(2):250-4. Marder SR, Daniel DG, Alphs L, Awad AG, Keefe RS. PMID: 21270473; PMCID: PMC3044631.
-
Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study. J Clin Pharmacol. 2011 Nov; 51(11):1587-91. Wessels AM, Bies RR, Pollock BG, Schneider LS, Lieberman JA, Stroup S, Li CH, Coley K, Kirshner MM, Marder SR. PMID: 21209243.
-
Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia. Am J Psychiatry. 2011 Mar; 168(3):286-92. Subotnik KL, Nuechterlein KH, Ventura J, Gitlin MJ, Marder S, Mintz J, Hellemann GS, Thornton LA, Singh IR. PMID: 21205805; PMCID: PMC5069345.
-
The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study. Schizophr Res. 2011 Mar; 126(1-3):124-31. Kern RS, Gold JM, Dickinson D, Green MF, Nuechterlein KH, Baade LE, Keefe RS, Mesholam-Gately RI, Seidman LJ, Lee C, Sugar CA, Marder SR. PMID: 21159492; PMCID: PMC3050090.
-
A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry. 2011 Mar 01; 69(5):442-9. Buchanan RW, Keefe RS, Lieberman JA, Barch DM, Csernansky JG, Goff DC, Gold JM, Green MF, Jarskog LF, Javitt DC, Kimhy D, Kraus MS, McEvoy JP, Mesholam-Gately RI, Seidman LJ, Ball MP, McMahon RP, Kern RS, Robinson J, Marder SR. PMID: 21145041; PMCID: PMC3058394.
-
The cultural adaptability of intermediate measures of functional outcome in schizophrenia. Schizophr Bull. 2012 May; 38(3):630-41. Velligan DI, Rubin M, Fredrick MM, Mintz J, Nuechterlein KH, Schooler NR, Jaeger J, Peters NM, Buller R, Marder SR, Dube S. PMID: 21134973; PMCID: PMC3329974.
-
Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-Alzheimer's disease trial. J Clin Psychopharmacol. 2010 Dec; 30(6):683-7. Wessels AM, Pollock BG, Anyama NG, Schneider LS, Lieberman JA, Marder SR, Bies RR. PMID: 21105282.
-
Routine outcomes monitoring to support improving care for schizophrenia: report from the VA Mental Health QUERI. Community Ment Health J. 2011 Apr; 47(2):123-35. Young AS, Niv N, Chinman M, Dixon L, Eisen SV, Fischer EP, Smith J, Valenstein M, Marder SR, Owen RR. PMID: 20658320; PMCID: PMC3058510.
-
The brief negative symptom scale: psychometric properties. Schizophr Bull. 2011 Mar; 37(2):300-5. Kirkpatrick B, Strauss GP, Nguyen L, Fischer BA, Daniel DG, Cienfuegos A, Marder SR. PMID: 20558531; PMCID: PMC3044634.
-
The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? Schizophr Bull. 2011 Nov; 37(6):1209-17. Buchanan RW, Keefe RS, Umbricht D, Green MF, Laughren T, Marder SR. PMID: 20410237; PMCID: PMC3196938.
-
Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia. Schizophr Bull. 2011 Sep; 37(5):1057-65. Keefe RS, Vinogradov S, Medalia A, Silverstein SM, Bell MD, Dickinson D, Ventura J, Marder SR, Stroup TS. PMID: 20194249; PMCID: PMC3160227.
-
Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation. J Clin Psychiatry. 2010 Apr; 71(4):433-41. Marder SR, Sorsaburu S, Dunayevich E, Karagianis JL, Dawe IC, Falk DM, Dellva MA, Carlson JL, Cavazzoni PA, Baker RW. PMID: 20156413.
-
Apathy in first episode psychosis patients: one year follow up. Schizophr Res. 2010 Jan; 116(1):20-6. Faerden A, Finset A, Friis S, Agartz I, Barrett EA, Nesvåg R, Andreassen OA, Marder SR, Melle I. PMID: 19948392.
-
Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking. J Clin Pharmacol. 2010 Jan; 50(1):73-80. Jin Y, Pollock BG, Coley K, Miller D, Marder SR, Florian J, Schneider L, Lieberman J, Kirshner M, Bies RR. PMID: 19843655; PMCID: PMC3648660.
-
A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry. 2009 Oct; 70(10):1348-57. Kane JM, Correll CU, Goff DC, Kirkpatrick B, Marder SR, Vester-Blokland E, Sun W, Carson WH, Pikalov A, Assunção-Talbott S. PMID: 19906340.
-
A brief cognitive assessment tool for schizophrenia: construction of a tool for clinicians. Schizophr Bull. 2011 May; 37(3):538-45. Hurford IM, Marder SR, Keefe RS, Reise SP, Bilder RM. PMID: 19776205; PMCID: PMC3080688.
-
Psychosocial treatments to promote functional recovery in schizophrenia. Schizophr Bull. 2009 Mar; 35(2):347-61. Kern RS, Glynn SM, Horan WP, Marder SR. PMID: 19176470; PMCID: PMC2659313.
-
The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. J Clin Psychiatry. 2009 Jan; 70(1):25-35. Janicak PG, Glick ID, Marder SR, Crandall DT, McQuade RD, Marcus RN, Eudicone JM, Assunção-Talbott S. PMID: 19192472.
-
Better pharmacotherapy for schizophrenia: what does the future hold? Curr Psychiatry Rep. 2008 Aug; 10(4):352-8. Webber MA, Marder SR. PMID: 18627675.
-
Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. Br J Clin Pharmacol. 2008 Nov; 66(5):629-39. Feng Y, Pollock BG, Coley K, Marder S, Miller D, Kirshner M, Aravagiri M, Schneider L, Bies RR. PMID: 18771484; PMCID: PMC2661978.
-
Definitions of the term 'recovered' in schizophrenia and other disorders. Psychopathology. 2008; 41(5):271-8. Faerden A, Nesvåg R, Marder SR. PMID: 18594161.
-
Treatment of agitation in patients with schizophrenia. J Clin Psychiatry. 2008 Jun; 69(6):e17. Marder SR. PMID: 18683992.
-
It is time to take a stand for medical research and against terrorism targeting medical scientists. Biol Psychiatry. 2008 Apr 15; 63(8):725-7. Krystal JH, Carter CS, Geschwind D, Manji HK, March JS, Nestler EJ, Zubieta JK, Charney DS, Goldman D, Gur RE, Lieberman JA, Roy-Byrne P, Rubinow DR, Anderson SA, Barondes S, Berman KF, Blair J, Braff DL, Brown ES, Calabrese JR, Carlezon WA, Cook EH, Davidson RJ, Davis M, Desimone R, Drevets WC, Duman RS, Essock SM, Faraone SV, Freedman R, Friston KJ, Gelernter J, Geller B, Gill M, Gould E, Grace AA, Grillon C, Gueorguieva R, Hariri AR, Innis RB, Jones EG, Kleinman JE, Koob GF, Krystal AD, Leibenluft E, Levinson DF, Levitt PR, Lewis DA, Liberzon I, Lipska BK, Marder SR, Markou A, Mason GF, McDougle CJ, McEwen BS, McMahon FJ, Meaney MJ, Meltzer HY, Merikangas KR, Meyer-Lindenberg A, Mirnics K, Monteggia LM, Neumeister A, O'Brien CP, Owen MJ, Pine DS, Rapoport JL, Rauch SL, Robbins TW, Rosenbaum JF, Rosenberg DR, Ross CA, Rush AJ, Sackeim HA, Sanacora G, Schatzberg AF, Shaham Y, Siever LJ, Sunderland T, Tecott LH, Thase ME, Todd RD, Weissman MM, Yehuda R, Yoshikawa T, Young EA, McCandless R. PMID: 18371494.
-
Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia. Psychiatr Serv. 2008 Mar; 59(3):315-7. Zhu B, Ascher-Svanum H, Shi L, Faries D, Montgomery W, Marder SR. PMID: 18308914.
-
Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol. 2008 Feb; 48(2):157-65. Bigos KL, Pollock BG, Coley KC, Miller DD, Marder SR, Aravagiri M, Kirshner MA, Schneider LS, Bies RR. PMID: 18199892.
-
Time to rehospitalization of clozapine versus risperidone in the naturalistic treatment of comorbid alcohol use disorder and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2008 May 15; 32(4):984-8. Kim JH, Kim D, Marder SR. PMID: 18262321.
-
The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008 Feb; 165(2):203-13. Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, Fenton WS, Frese FJ, Gold JM, Goldberg T, Heaton RK, Keefe RS, Kraemer H, Mesholam-Gately R, Seidman LJ, Stover E, Weinberger DR, Young AS, Zalcman S, Marder SR. PMID: 18172019.
-
The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am J Psychiatry. 2008 Feb; 165(2):214-20. Kern RS, Nuechterlein KH, Green MF, Baade LE, Fenton WS, Gold JM, Keefe RS, Mesholam-Gately R, Mintz J, Seidman LJ, Stover E, Marder SR. PMID: 18172018.
-
Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study. Am J Psychiatry. 2008 Feb; 165(2):221-8. Green MF, Nuechterlein KH, Kern RS, Baade LE, Fenton WS, Gold JM, Keefe RS, Mesholam-Gately R, Seidman LJ, Stover E, Marder SR. PMID: 18172017.
-
Selective corticostriatal dysfunction in schizophrenia: examination of motor and cognitive skill learning. Neuropsychology. 2008 Jan; 22(1):100-9. Foerde K, Poldrack RA, Khan BJ, Sabb FW, Bookheimer SY, Bilder RM, Guthrie D, Granholm E, Nuechterlein KH, Marder SR, Asarnow RF. PMID: 18211159.
-
Chronic restlessness with antipsychotics. Am J Psychiatry. 2007 Nov; 164(11):1648-54. Bratti IM, Kane JM, Marder SR. PMID: 17974927.
-
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry. 2007 Nov; 68(11):1751-62. Moore TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, Essock SM, Finnerty M, Marder SR, Miller DD, McEvoy JP, Robinson DG, Schooler NR, Shon SP, Stroup TS, Miller AL. PMID: 18052569.
-
Newer antipsychotics and the differences between clinical experiences and clinical trials. Interview by Norman Sussman, MD. CNS Spectr. 2007 Nov; 12(11):812-5. Marder SR. PMID: 18084854.
-
Social Cognition and Neurocognition: Effects of Risperidone, Olanzapine, and Haloperidol. Am J Psychiatry. 2007 Oct 01; 164(10):1585-1592. Sergi M, Green M, Widmark C, Reist C, Erhart S, Braff D, Kee K, Marder S, Mintz J. PMID: 22688151.
-
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry. 2007 Oct; 164(10):1593-602. Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, Heresco-Levy U, Carpenter WT. PMID: 17898352.
-
New paradigms for treatment development. Schizophr Bull. 2007 Sep; 33(5):1093-9. Stover EL, Brady L, Marder SR. PMID: 17673495; PMCID: PMC2632353.
-
Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial. Schizophr Res. 2007 Sep; 95(1-3):134-42. Wynn JK, Green MF, Sprock J, Light GA, Widmark C, Reist C, Erhart S, Marder SR, Mintz J, Braff DL. PMID: 17662577; PMCID: PMC2716219.
-
Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry. 2007 Dec 15; 62(12):1363-70. Marder SR, Kramer M, Ford L, Eerdekens E, Lim P, Eerdekens M, Lowy A. PMID: 17601495.
-
Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials. J Clin Psychiatry. 2007 May; 68(5):662-8. Marder SR, West B, Lau GS, Pultz JA, Pikalov A, Marcus RN, Gutierrez-Esteinou R, Crandall DT. PMID: 17503974.
-
A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia. J Clin Psychiatry. 2007 May; 68(5):705-10. Pierre JM, Peloian JH, Wirshing DA, Wirshing WC, Marder SR. PMID: 17503979.
-
Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr Serv. 2007 Apr; 58(4):482-8. Shi L, Ascher-Svanum H, Zhu B, Faries D, Montgomery W, Marder SR. PMID: 17412849.
-
Lessons from each drug trial. Am J Psychiatry. 2007 Mar; 164(3):375-6. Marder SR. PMID: 17329457.
-
Switch or stay? Am J Psychiatry. 2006 Dec; 163(12):2032-3. Davis JM, Marder SR, Tamminga CA. PMID: 17151147.
-
Determination of ziprasidone in human plasma by liquid chromatography-electrospray tandem mass spectrometry and its application to plasma level determination in schizophrenia patients. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Mar 01; 847(2):237-44. Aravagiri M, Marder SR, Pollock B. PMID: 17098485.
-
Initiatives to promote the discovery of drugs to improve cognitive function in severe mental illness. J Clin Psychiatry. 2006 Jul; 67(7):e03. Marder SR. PMID: 17107228.
-
Treatment of schizophrenia negative symptoms: future prospects. Schizophr Bull. 2006 Apr; 32(2):234-7. Erhart SM, Marder SR, Carpenter WT. PMID: 16492797; PMCID: PMC2632230.
-
The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006 Apr; 32(2):214-9. Kirkpatrick B, Fenton WS, Carpenter WT, Marder SR. PMID: 16481659; PMCID: PMC2632223.
-
The NIMH-MATRICS project for developing cognition-enhancing agents for schizophrenia. Dialogues Clin Neurosci. 2006; 8(1):109-13. Marder SR. PMID: 16640121; PMCID: PMC3181758.
-
Drug initiatives to improve cognitive function. J Clin Psychiatry. 2006; 67 Suppl 9:31-5; discussion 36-42. Marder SR. PMID: 16965187.
-
A review of agitation in mental illness: treatment guidelines and current therapies. J Clin Psychiatry. 2006; 67 Suppl 10:13-21. Marder SR. PMID: 16965191.
-
Commentary on "TM and our models of informed consent" by Charles W. Lidz. Behav Sci Law. 2006; 24(4):547-52. Charuvastra A, Marder S. PMID: 16883615.
-
Clinical utility of magnetic resonance imaging radiographs for suspected organic syndromes in adult psychiatry. J Clin Psychiatry. 2005 Aug; 66(8):968-73. Erhart SM, Young AS, Marder SR, Mintz J. PMID: 16086610.
-
Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2005 May; 66(5):638-41. Glick ID, Marder SR. PMID: 15889952.
-
Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategy. J Clin Psychopharmacol. 2005 Apr; 25(2):170-4. Albers LJ, Ozdemir V, Marder SR, Raggi MA, Aravagiri M, Endrenyi L, Reist C. PMID: 15738749.
-
Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005 Mar; 162(3):441-9. Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR. PMID: 15741458.
-
Subjective experiences on antipsychotic medications: synthesis and conclusions. Acta Psychiatr Scand Suppl. 2005; (427):43-6. Marder SR. PMID: 15877721.
-
Anterior cingulate dysfunction during choice anticipation in schizophrenia. Psychiatry Res. 2004 Dec 15; 132(2):117-30. Quintana J, Wong T, Ortiz-Portillo E, Marder SR, Mazziotta JC. PMID: 15598546.
-
Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res. 2004 Dec 15; 72(1):5-9. Marder SR, Fenton W. PMID: 15531402.
-
The heterogeneity of schizophrenia in disease states. Schizophr Res. 2004 Nov 01; 71(1):83-95. Mohr PE, Cheng CM, Claxton K, Conley RR, Feldman JJ, Hargreaves WA, Lehman AF, Lenert LA, Mahmoud R, Marder SR, Neumann PJ. PMID: 15374576.
-
Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry. 2004 Sep 01; 56(5):301-7. Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S, Fenton WS, Frese F, Goldberg TE, Heaton RK, Keefe RS, Kern RS, Kraemer H, Stover E, Weinberger DR, Zalcman S, Marder SR. PMID: 15336511.
-
Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004 Aug; 161(8):1334-49. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Kane JM, Lieberman JA, Schooler NR, Covell N, Stroup S, Weissman EM, Wirshing DA, Hall CS, Pogach L, Pi-Sunyer X, Bigger JT, Friedman A, Kleinberg D, Yevich SJ, Davis B, Shon S. PMID: 15285957.
-
Panic disorder: psychopathology, medical management and dental implications. J Am Dent Assoc. 2004 Jun; 135(6):771-8; quiz 796-7. Friedlander AH, Marder SR, Sung EC, Child JS. PMID: 15270162.
-
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry. 2004 Apr; 65(4):500-8. Miller A, Hall CS, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, Ereshefsky L, Essock SM, Finnerty M, Marder SR, Miller DD, McEvoy JP, Rush AJ, Saeed SA, Schooler NR, Shon SP, Stroup S, Tarin-Godoy B. PMID: 15119912.
-
Do clozapine and risperidone affect social competence and problem solving? Am J Psychiatry. 2004 Feb; 161(2):364-7. Bellack AS, Schooler NR, Marder SR, Kane JM, Brown CH, Yang Y. PMID: 14754789.
-
Posttraumatic stress disorder: psychopathology, medical management, and dental implications. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 Jan; 97(1):5-11. Friedlander AH, Friedlander IK, Marder SR. PMID: 14716250.
-
Schizophrenia, IX: Cognition in schizophrenia--the MATRICS initiative. Am J Psychiatry. 2004 Jan; 161(1):25. Marder SR, Fenton W, Youens K. PMID: 14702244.
-
Intra- and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone. Ther Drug Monit. 2003 Dec; 25(6):657-64. Aravagiri M, Marder SR, Nuechterlein KH, Gitlin MJ. PMID: 14639051.
-
Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. Am J Psychiatry. 2003 Aug; 160(8):1405-12. Marder SR, Glynn SM, Wirshing WC, Wirshing DA, Ross D, Widmark C, Mintz J, Liberman RP, Blair KE. PMID: 12900301.
-
Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2003 Jul; 60(7):681-90. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR. PMID: 12860772.
-
Right lateral fusiform gyrus dysfunction during facial information processing in schizophrenia. Biol Psychiatry. 2003 Jun 15; 53(12):1099-112. Quintana J, Wong T, Ortiz-Portillo E, Marder SR, Mazziotta JC. PMID: 12814861.
-
Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res. 2003 Jun 01; 61(2-3):123-36. Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T. PMID: 12729864.
-
Alcohol abuse and dependence: psychopathology, medical management and dental implications. J Am Dent Assoc. 2003 Jun; 134(6):731-40. Friedlander AH, Marder SR, Pisegna JR, Yagiela JA. PMID: 12839410; PMCID: PMC6736549.
-
Prefrontal-posterior parietal networks in schizophrenia: primary dysfunctions and secondary compensations. Biol Psychiatry. 2003 Jan 01; 53(1):12-24. Quintana J, Wong T, Ortiz-Portillo E, Kovalik E, Davidson T, Marder SR, Mazziotta JC. PMID: 12513941.
-
Clinical guidelines: Dosing and switching strategies for long-acting risperidone. J Clin Psychiatry. 2003; 64 Suppl 16:41-6. Marder SR, Conley R, Ereshefsky L, Kane JM, Turner MS. PMID: 14680418.
-
Overview of partial compliance. J Clin Psychiatry. 2003; 64 Suppl 16:3-9. Marder SR. PMID: 14680412.
-
Can risperidone reduce cocaine use in substance abusing schizophrenic patients? J Clin Psychopharmacol. 2002 Dec; 22(6):629-30. Tsuang JW, Eckman T, Marder S, Tucker D. PMID: 12454567.
-
Olanzapine treatment for patients with schizophrenia and cocaine abuse. J Clin Psychiatry. 2002 Dec; 63(12):1180 -1. Tsuang J, Marder SR, Han A, Hsieh W. PMID: 12530415.
-
Risperidone, 2 mg/day vs. 4 mg/day, in first-episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioning. J Clin Psychiatry. 2002 Oct; 63(10):885-91. Merlo MC, Hofer H, Gekle W, Berger G, Ventura J, Panhuber I, Latour G, Marder SR. PMID: 12416598.
-
The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry. 2002 Oct; 63(10):856-65. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC. PMID: 12416594.
-
Bipolar I disorder: psychopathology, medical management and dental implications. J Am Dent Assoc. 2002 Sep; 133(9):1209-17. Friedlander AH, Friedlander IK, Marder SR. PMID: 12356252.
-
Sexual side effects of novel antipsychotic medications. Schizophr Res. 2002 Jul 01; 56(1-2):25-30. Wirshing DA, Pierre JM, Marder SR, Saunders CS, Wirshing WC. PMID: 12084416.
-
The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol Psychiatry. 2002 Jun 15; 51(12):972-8. Green MF, Marder SR, Glynn SM, McGurk SR, Wirshing WC, Wirshing DA, Liberman RP, Mintz J. PMID: 12062881.
-
Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. J Clin Psychiatry. 2002 May; 63(5):420-4. Umbricht DS, Wirshing WC, Wirshing DA, McMeniman M, Schooler NR, Marder SR, Kane JM. PMID: 12019667.
-
The psychopathology, medical management and dental implications of schizophrenia. J Am Dent Assoc. 2002 May; 133(5):603-10; quiz 624-5. Friedlander AH, Marder SR. PMID: 12036166.
-
Supplementing clinic-based skills training with manual-based community support sessions: effects on social adjustment of patients with schizophrenia. Am J Psychiatry. 2002 May; 159(5):829-37. Glynn SM, Marder SR, Liberman RP, Blair K, Wirshing WC, Wirshing DA, Ross D, Mintz J. PMID: 11986138.
-
A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry. 2002 Apr; 159(4):554-60. Kane JM, Davis JM, Schooler N, Marder S, Casey D, Brauzer B, Mintz J, Conley R. PMID: 11925292.
-
Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate. Schizophr Res. 2002 Jan 01; 53(1-2):25-30. Marder SR, Aravagiri M, Wirshing WC, Wirshing DA, Lebell M, Mintz J. PMID: 11728835.
-
The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophr Bull. 2002; 28(1):5-16. Marder SR, Essock SM, Miller AL, Buchanan RW, Davis JM, Kane JM, Lieberman J, Schooler NR. PMID: 12047022.
-
Can clinical practice guide a research agenda? Schizophr Bull. 2002; 28(1):127-9. Marder SR. PMID: 12047012.
-
In vivo amplified skills training: promoting generalization of independent living skills for clients with schizophrenia. Psychiatry. 2002; 65(2):137-55. Liberman RP, Glynn S, Blair KE, Ross D, Marder SR. PMID: 12108138.
-
Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats. Psychopharmacology (Berl). 2002 Feb; 159(4):424-31. Aravagiri M, Marder SR. PMID: 11823895.
-
Antipsychotic drugs and relapse prevention. Schizophr Res. 1999 Mar 01; 35 Suppl:S87-92. Marder SR. PMID: 10190229.
-
Two-year outcome of social skills training and group psychotherapy for outpatients with schizophrenia. Am J Psychiatry. 1996 Dec; 153(12):1585-92. Marder SR, Wirshing WC, Mintz J, McKenzie J, Johnston K, Eckman TA, Lebell M, Zimmerman K, Liberman RP. PMID: 8942455.
US